image
Healthcare - Biotechnology - NASDAQ - US
$ 16.76
-1.35 %
$ 1.69 B
Market Cap
-3.64
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BEAM stock under the worst case scenario is HIDDEN Compared to the current market price of 16.8 USD, Beam Therapeutics Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BEAM stock under the base case scenario is HIDDEN Compared to the current market price of 16.8 USD, Beam Therapeutics Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BEAM stock under the best case scenario is HIDDEN Compared to the current market price of 16.8 USD, Beam Therapeutics Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BEAM

image
$36.0$36.0$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
63.5 M REVENUE
-83.18%
-416 M OPERATING INCOME
-135.47%
-377 M NET INCOME
-184.28%
-347 M OPERATING CASH FLOW
-132.75%
185 M INVESTING CASH FLOW
157.53%
7.74 M FINANCING CASH FLOW
-97.20%
7.47 M REVENUE
-75.16%
-119 M OPERATING INCOME
-19.24%
-109 M NET INCOME
-20.94%
-104 M OPERATING CASH FLOW
-36.04%
-125 M INVESTING CASH FLOW
-99.06%
473 M FINANCING CASH FLOW
13645.03%
Balance Sheet Beam Therapeutics Inc.
image
Current Assets 878 M
Cash & Short-Term Investments 851 M
Receivables 0
Other Current Assets 27.4 M
Non-Current Assets 226 M
Long-Term Investments 0
PP&E 216 M
Other Non-Current Assets 9.4 M
77.07 %19.59 %Total Assets$1.1b
Current Liabilities 182 M
Accounts Payable 3.87 M
Short-Term Debt 13.5 M
Other Current Liabilities 165 M
Non-Current Liabilities 188 M
Long-Term Debt 0
Other Non-Current Liabilities 188 M
3.64 %44.49 %50.83 %Total Liabilities$370.3m
EFFICIENCY
Earnings Waterfall Beam Therapeutics Inc.
image
Revenue 63.5 M
Cost Of Revenue 0
Gross Profit 41.6 M
Operating Expenses 479 M
Operating Income -416 M
Other Expenses -38.8 M
Net Income -377 M
100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)64m042m(479m)(416m)39m(377m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
65.48% GROSS MARGIN
65.48%
-654.25% OPERATING MARGIN
-654.25%
-593.13% NET MARGIN
-593.13%
-51.36% ROE
-51.36%
-34.13% ROA
-34.13%
-44.44% ROIC
-44.44%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Beam Therapeutics Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -377 M
Depreciation & Amortization 21.9 M
Capital Expenditures -8.95 M
Stock-Based Compensation 0
Change in Working Capital -110 M
Others -104 M
Free Cash Flow -356 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Beam Therapeutics Inc.
image
Wall Street analysts predict an average 1-year price target for BEAM of $47 , with forecasts ranging from a low of $25 to a high of $69 .
BEAM Lowest Price Target Wall Street Target
25 USD 49.16%
BEAM Average Price Target Wall Street Target
47 USD 180.43%
BEAM Highest Price Target Wall Street Target
69 USD 311.69%
Price
Max Price Target
Min Price Target
Average Price Target
7070606050504040303020201010Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Beam Therapeutics Inc.
image
Sold
0-3 MONTHS
372 K USD 1
3-6 MONTHS
2.45 M USD 5
6-9 MONTHS
4.18 M USD 4
9-12 MONTHS
1.5 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases Positive results released from updated data with 17 SCD patients with VOC from the phase 1/2 BEACON study. No VOC after engraftment and >60% HbF induction. Additional results of 30 SCD patients from phase 1/2 BEACON study using BEAM-101, expected in the 2nd half of 2025. The global sickle cell disease market is expected to reach $12.38 billion by 2032. seekingalpha.com - 1 week ago
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to globenewswire.com - 2 weeks ago
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? zacks.com - 4 weeks ago
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease. zacks.com - 4 weeks ago
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). globenewswire.com - 1 month ago
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effective therapies that can treat the entire spectrum of disease. globenewswire.com - 1 month ago
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 globenewswire.com - 1 month ago
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 11:00 a.m. globenewswire.com - 1 month ago
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effective therapies that can treat the entire spectrum of disease. globenewswire.com - 1 month ago
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development. zacks.com - 1 month ago
Why Beam Therapeutics Stock Tanked on Tuesday Precision gene-editing company Beam Therapeutics (BEAM -19.68%) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced downwards to a more than 19% loss on the day. fool.com - 1 month ago
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.21 per share a year ago. zacks.com - 1 month ago
8. Profile Summary

Beam Therapeutics Inc. BEAM

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.69 B
Dividend Yield 0.00%
Description Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Contact 238 Main Street, Cambridge, MA, 02142 https://www.beamtx.com
IPO Date Feb. 6, 2020
Employees 393
Officers Dr. Manmohan Singh Ph.D. Chief Technology Officer Dr. J. Keith Joung M.D., Ph.D. Co-Founder Dr. Feng Zhang Ph.D. Co-Founder Dr. Amy Simon M.D. Chief Medical Officer Dr. David R. Liu Ph.D. Co-Founder Dr. Gopi Shanker Ph.D. Chief Scientific Officer Dr. Giuseppe Ciaramella Ph.D. President Mr. John M. Evans M.B.A. Chief Executive Officer & Director Mr. Sravan Kumar Emany Chief Financial Officer Dr. Christine P. Bellon J.D., Ph.D. Senior Vice President, Chief Legal Officer & Corporate Secretary